Based on the emerging evidence showing that receptor derived peptide fragments are involved in cancer development and progression, Del Rio Moreno et al. demonstrated that the truncated variant of somatostatin receptor subtype 5 (SST5TMD4) derived peptides could contribute to the strong oncogenic role of SST5TMD4 observed in multiple cancer pathologies and represent potential candidates to identify new diagnostic, prognostic, and therapeutic targets in oncology [33]. This evidence concerns the gene SSTR5 and cancer.